GUIDELINES IN DERMATOLOGY

gdkapak

BEHÇET’S DISEASE

Nazlı Caf1
Sefa Yüksel2

1Başakşehir Çam and Sakura City Hospital, Department of Dermatology, İstanbul, Türkiye
2Başakşehir Çam and Sakura City Hospital, Department of Dermatology, İstanbul, Türkiye

Caf N, Yüksel S. Behçet’s Disease. In: Kutlubay Z, editor. Guidelines in Dermatology. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.47-54.

ABSTRACT

Behçet’s disease is a systemic vasculitis that can involve many tissues and organs, although mucocutaneous involvement is the most common and earliest manifestation. Its etiopathogenesis has not been fully elucidated and epidemiological data are highly variable. Treatment guidelines for the treatment of Behçet’s disease are not diverse. Many topical and systemic agents, primarily steroids and colchicine, may be used for the treatment of mucocutaneous Behçet’s disease. Apremilast and biological agents are relatively novel and considered effective drugs. The treatment plan for Behçet’s treatment varies depending on the affected organs and their severity. In this article, only the treatment of mucocutaneous Behçet’s disease will be discussed.

Keywords: Apremilast; Behçet’s disease; Colchicine; Erythema nodosum; Oral ulcer

Referanslar

  1. Hatemi G, Seyahi E, Fresko I, Talarico R, Uçar D, Hamuryudan V. Behçet's syndrome: one year in review 2024. Clinical and experimental rheumatology. 2024;42(10):1999-2007. [Crossref]
  2. Nakamura K, Iwata Y, Asai J, et al. Guidelines for the treatment of skin and mucosal lesions in Behçet's disease: A secondary publication. J Dermatol. 2020;47(3):223-235. [Crossref]  [PubMed]
  3. Kone-Paut I, Barete S, Bodaghi B, Deiva K, Desbois AC, Galeotti C, et. al. French recommendations for the management of Behçet's disease. Orphanet journal of rare diseases. 2021;16(Suppl 1):352. [Crossref]  [PubMed]  [PMC]
  4. Chen J, Yao X. (2021). A Contemporary Review of Behcet's Syndrome. Clinical reviews in allergy & immunology, 2021;61(3):363-376. [Crossref]  [PubMed]
  5. Kiafar M, Faezi ST, Kasaeian A, Baghdadi A, Kakaei S, Mousavi SA, et. al. Diagnosis of Behçet's disease: clinical characteristics, diagnostic criteria, and differential diagnoses. BMC rheumatology. 2021;5(1):2. [Crossref]  [PubMed]  [PMC]
  6. Watts RA, Hatemi G, Burns JC, Mohammad AJ. Global epidemiology of vasculitis. Nature reviews. Rheumatology. 2022;18(1):22-34. [Crossref]  [PubMed]  [PMC]
  7. Alpsoy E, Leccese P, Ergun T. Editorial: Behçet's Disease: Epidemiology, Etiopathogenesis, Diagnosis and Treatment. Front Med (Lausanne). 2021;8:794874. Published 2021 Nov5. [Crossref]  [PubMed]  [PMC]
  8. Alibaz-Oner F, Direskeneli H. Advances in the Treatment of Behcet's Disease. Curr Rheumatol Rep. 2021;23(6):47. Published 2021 May 20. [Crossref]  [PubMed]  [PMC]
  9. Alpsoy E, Leccese P, Emmi G, Ohno S. Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach. Frontiers in medicine. 2021;8:624795. [Crossref]  [PubMed]  [PMC]
  10. Hatemi G, Christensen R, Bang D, Bodaghi B, Celik AF, Fortune F, et. al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Annals of the rheumatic diseases. 2018;77(6):808-818. [Crossref]  [PubMed]
  11. Scherrer MAR, Rocha VB, Garcia LC. Behçet's disease: review with emphasis on dermatological aspects. Anais brasileiros de dermatologia, 2017;92(4):452-464. [Crossref]  [PubMed]  [PMC]
  12. He R, Zhao S, Cui M, Chen Y, Ma J, Li J, et. al. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations. Frontiers in immunology. 2023;14:1234535. [Crossref]  [PubMed]  [PMC]
  13. Kaya TI, Tursen U, Baz K, Ikizoglu G, Dusmez D. Severe erythema nodosum due to Behçet's disease responsive to erythromycin. The Journal of dermatological treatment. 2003;14(2):124-127. [Crossref]  [PubMed]
  14. Greco A, De Virgilio A, Ralli M, Ciofalo A, Mancini P, Attanasio G, et. al. (2018). Behçet's disease: New insights into pathophysiology, clinical features and treatment options. Autoimmunity reviews. 2018;17(6):567-575. [Crossref]  [PubMed]
  15. Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Seminars in arthritis and rheumatism. 2011;41(1):61-70. [Crossref]  [PubMed]
  16. van der Houwen TB, van Hagen PM, van Laar JAM. Immunopathogenesis of Behçet's disease and treatment modalities. Seminars in arthritis and rheumatism. 2022;52:151956. [Crossref]  [PubMed]
  17. Wu KK, Dao H Jr. Off-label dermatologic uses of IL-17 inhibitors. The Journal of dermatological treatment. 2022;33(1):41-47. [Crossref]  [PubMed]
  18. Ozguler Y, Ozdede A, Hatemi G. Recent Insights into the Management of Behçet Syndrome. Journal of inflammation research. 2021;14:3429-3441. [Crossref]  [PubMed]  [PMC]
  19. Comarmond C, Wechsler B, Bodaghi B, Cacoub P, Saadoun D. Biotherapies in Behçet's disease. Autoimmunity reviews. 2014;13(7):762-769. [Crossref]  [PubMed]
  20. Mease PJ, Hatemi G, Paris M, Cheng S, Maes P, Zhang W, et. al. Apremilast Long-Term Safety Up to 5 Years from 15 Pooled Randomized, Placebo-Controlled Studies of Psoriasis, Psoriatic Arthritis, and Behçet's Syndrome. American journal of clinical dermatology. 2023;24(5):809-820. [Crossref]  [PubMed]  [PMC]
  21. Yenice Çakmak G, Şehirli AÖ. (2022). Treatment of Behçet's Disease and Current Approaches. Journal of Faculty of Pharmacy of Ankara University. 2022;46(2):619-650. [Crossref]